In its software, Lykos describes MDMA to be a catalyst for the therapeutic system, which is why it gained much focus. That is not envisioned to generally be as much of the hold-up for other psychedelics, though. “The rest of us are finding out molecules that do not need exactly the same diploma of therapy,” says Kabir Nath, CEO of Compass Pathw